PFS of CLL patients receiving frontline chemoimmunotherapy
Group . | PFS, mo . | Hazard ratios . | ||
---|---|---|---|---|
Median . | 95% CI . | HR . | 95% CI . | |
FCR | 59.10 | 55.50-64.90 | Reference | Reference |
Controls (non-FCR regimen) | 38.15 | 34.07-41.65 | 1.65 | 1.42-1.91 |
BR | 38.41 | 33.96-44.82 | 1.57 | 1.27-1.94 |
FC | 35.32 | 31.14-41.01 | 1.70 | 1.40-2.05 |
FCCam | Not evaluable* | Not evaluable | 1.88 | 0.76-4.66 |
PCR | Not evaluable† | Not evaluable | 1.46 | 0.88-2.43 |
Classified by regimen and IGHV mutation status | ||||
FCR IGHVmutated | Not reached | Not evaluable | Reference | Reference |
FCR IGHVunmutated | 42.88 | 38.02-51.85 | 2.89 | 2.16-3.87 |
BR IGHVmutated | 55.37 | Not evaluable | 1.70 | 1.06-2.71 |
BR IGHVunmutated | 33.60 | 29.49-38.33 | 4.10 | 2.95-5.61 |
FC IGHVmutated | 45.17 | 37.84-56.89 | 2.54 | 1.81-3.57 |
FC IGHVunmutated | 30.63 | 25.41-33.66 | 4.30 | 3.18-5.81 |
Classified by IGHV mutation status | ||||
FCR IGHVmutated | Not reached | Not evaluable | Reference | Reference |
FCR IGHVunmutated | 42.88 | 38.02-51.85 | 2.91 | 2.17-3.89 |
Control IGHVmutated | 52.02 | 43.12-63.75 | 2.25 | 1.64-3.10 |
Control IGHVunmutated | 32.40 | 29.26-34.61 | 4.23 | 3.19-5.61 |
Group . | PFS, mo . | Hazard ratios . | ||
---|---|---|---|---|
Median . | 95% CI . | HR . | 95% CI . | |
FCR | 59.10 | 55.50-64.90 | Reference | Reference |
Controls (non-FCR regimen) | 38.15 | 34.07-41.65 | 1.65 | 1.42-1.91 |
BR | 38.41 | 33.96-44.82 | 1.57 | 1.27-1.94 |
FC | 35.32 | 31.14-41.01 | 1.70 | 1.40-2.05 |
FCCam | Not evaluable* | Not evaluable | 1.88 | 0.76-4.66 |
PCR | Not evaluable† | Not evaluable | 1.46 | 0.88-2.43 |
Classified by regimen and IGHV mutation status | ||||
FCR IGHVmutated | Not reached | Not evaluable | Reference | Reference |
FCR IGHVunmutated | 42.88 | 38.02-51.85 | 2.89 | 2.16-3.87 |
BR IGHVmutated | 55.37 | Not evaluable | 1.70 | 1.06-2.71 |
BR IGHVunmutated | 33.60 | 29.49-38.33 | 4.10 | 2.95-5.61 |
FC IGHVmutated | 45.17 | 37.84-56.89 | 2.54 | 1.81-3.57 |
FC IGHVunmutated | 30.63 | 25.41-33.66 | 4.30 | 3.18-5.81 |
Classified by IGHV mutation status | ||||
FCR IGHVmutated | Not reached | Not evaluable | Reference | Reference |
FCR IGHVunmutated | 42.88 | 38.02-51.85 | 2.91 | 2.17-3.89 |
Control IGHVmutated | 52.02 | 43.12-63.75 | 2.25 | 1.64-3.10 |
Control IGHVunmutated | 32.40 | 29.26-34.61 | 4.23 | 3.19-5.61 |